Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...

Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of limb-girdle muscular dystrophy (LGMD), a group of rare genetic disorders marked ...

In other recent news, Sarepta Therapeutics has been the focus of several analyst updates and regulatory developments concerning its gene therapy, ELEVIDYS, for Duchenne muscular dystrophy (DMD).

In other recent news, Sarepta Therapeutics has been the focus of several analyst updates and regulatory developments concerning its gene therapy, ELEVIDYS, for Duchenne muscular dystrophy (DMD). Wells ...

The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...

The price target of $115 is based on a discounted cash flow (DCF) analysis, with a large portion of the valuation driven by the commercial success of Sarepta’s approved DMD products. These include the ...

Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) will be an option for many more patients in the US after the FDA expanded the breadth of its approved labelling. Elevidys ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal ...

Wells Fargo initiated coverage of Sarepta (SRPT) with an Overweight rating and $115 price target Despite the recent Gr5 AE case, the firm ...